1. Volume 67, Issue 1, Pages 23-31 (July 2017)
Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients – French ANRS CO13 HEPAVIH cohort 
Lionel Piroth, Linda Wittkop, Karine Lacombe, Eric Rosenthal, Camille Gilbert, Patrick Miailhes, Patrizia Carrieri, Julie Chas, Isabelle Poizot-Martin, Anne Gervais, Stéphanie Dominguez, Didier Neau, David Zucman, Eric Billaud, Philippe Morlat, Hugues Aumaitre, Caroline Lascoux-Combe, Anne Simon, Olivier Bouchaud, Elina Teicher, Firouzé Bani-Sadr, Laurent Alric, Daniel Vittecoq, François Boué, Claudine Duvivier, Marc-Antoine Valantin, Laure Esterle, François Dabis, Philippe Sogni, Dominique Salmon 
Journal of Hepatology 
Volume 67, Issue 1, Pages (July 2017)
DOI: /j.jhep
Copyright © 2017 European Association for the Study of the Liver Terms and Conditions

2. Fig. 1
Frequencies of sustained virological responses 12 weeks after end of therapy (SVR12). (A) Data grouped according to prescribed DAA regimen which was evaluated in adjusted exact logistic regression analysis (see Table 2A, B). (B∗, C and D∗) Data grouped according to the selected covariables which were evaluated in adjusted exact logistic regression analysis (see Table 2A, B). ∗Patients receiving SOF+RBV have been excluded from this analysis. Vertical bars represent 95% confidence intervals calculated using the exact binomial distribution.
Journal of Hepatology  , 23-31DOI: ( /j.jhep )
Copyright © 2017 European Association for the Study of the Liver Terms and Conditions

3. Journal of Hepatology 2017 67, 23-31DOI: (10.1016/j.jhep.2017.02.012)
Copyright © 2017 European Association for the Study of the Liver Terms and Conditions